ArticleBriefings in bioinformatics2025
DeepGraphMut: a graph-based deep learning method for cancer prognosis using somatic mutation profile.
Article in Briefings in bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Triad-LMF: a hierarchical low-rank multimodal fusion framework for robust cancer subtype classification using multi-omics data.BMC bioinformatics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Cancer remains a leading cause of morbidity and mortality worldwide. Despite advances in genomics, identifying clinically relevant subtypes of cancer remains challenging due to its complex and heterogeneous nature. In this work, we propose DeepGraphMut (DGM), a novel graph-based deep-learning pipeline that integrates somatic mutation data with protein-protein interaction (PPI) networks. By employing a graph autoencoder with a graph attention layer and a node-level attention decoder, DGM generates patient-specific clinically relevant encodings for unsupervised and supervised tasks. We demonstrate the effectiveness of DGM across 16 cancer types comprising of 7352 samples from The Cancer Genome Atlas (TCGA). Unsupervised clustering reveals distinct subtypes with significant survival differences in 11 cancer types. In supervised analysis using a Cox regression model, DGM demonstrates excellent performance in predicting survival outcomes, achieving a high concordance index (C-index) value in the range of 0.7 across most cancers, underscoring its robust predictive performance using only somatic mutation data. Furthermore, DGM outperforms its lightweight variant and network-based stratification methods in both unsupervised and supervised analyses. In summary, this study presents a promising approach for cancer subtype identification and prognosis, especially in resource-limited settings where multi-omics data may not be readily available. By leveraging the strengths of graph learning and network biology, DGM offers a valuable tool for advancing personalized medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.